TY - JOUR
T1 - Evidence from routine clinical practice
T2 - EMPRISE provides a new perspective on CVOTs
AU - Schernthaner, Guntram
AU - Karasik, Avraham
AU - Abraitienė, Agne
AU - Ametov, Alexander S.
AU - Gaàl, Zsolt
AU - Gumprecht, Janusz
AU - Janež, Andrej
AU - Kaser, Susanne
AU - Lalić, Katarina
AU - Mankovsky, Boris N.
AU - Moshkovich, Evgeny
AU - Past, Marju
AU - Prázný, Martin
AU - Radulian, Gabriela
AU - Smirčić Duvnjak, Lea
AU - Tkáč, Ivan
AU - Trušinskis, Kārlis
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/8/31
Y1 - 2019/8/31
N2 - EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
AB - EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
KW - CVOTs
KW - EMPA-REG OUTCOME
KW - EMPRISE
KW - Heart failure
KW - Real-world evidence
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85071771613&partnerID=8YFLogxK
U2 - 10.1186/s12933-019-0920-3
DO - 10.1186/s12933-019-0920-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31472683
AN - SCOPUS:85071771613
SN - 1475-2840
VL - 18
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 115
ER -
